Literature DB >> 15124022

Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine.

Toshio Iinuma1, Sadamu Homma, Tetsuo Noda, Donald Kufe, Tsuneya Ohno, Gotaro Toda.   

Abstract

Here we describe the effect of immunization with dendritic cells loaded with syngeneic tumor cells (DC/Ts) by polyethylene glycol treatment, on tumor development in adenomatous polyposis coli (APC) gene mutant mouse models, APC1309 and APC(Min-/+), in which adenomatous polyps of the gastrointestinal tracts develop with a high incidence. Treatment with DC/Ts prevented the development of gastrointestinal tumors, and coadministration of DC/Ts and IL-12 caused a further reduction in tumor incidence. Splenocytes from APC1309 mice treated with DC/Ts and IL-12 showed no cytotoxic activity toward the tumor cells, but serum antibody specific to them was detected. IgG from the treated mice exhibited cytotoxic activity against the tumor cells in vitro. Predominance of Th2 cell response over Th1 response was also suggested by ELISPOT assays in the treated mice. Depletion in vivo of CD4(+) T cells, not CD8(+) T cells, by the intraperitoneal administration of corresponding mAb's decreased the antitumor effect of DC/T inoculation. Immunofluorescence microscopic studies showed that Ig was attached to tumor cells in mice treated with DC/Ts and IL-12. These findings indicate that DC/T vaccination prevents tumor development through APC gene mutation and that its preventive effects are mediated by humoral antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15124022      PMCID: PMC398422          DOI: 10.1172/JCI17323

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

Review 1.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

Authors:  F M Marincola; E M Jaffee; D J Hicklin; S Ferrone
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

Review 2.  Antigen presentation and T cell stimulation by dendritic cells.

Authors:  Pierre Guermonprez; Jenny Valladeau; Laurence Zitvogel; Clotilde Théry; Sebastian Amigorena
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

3.  The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice.

Authors:  Shigeo Koido; Yasuhiro Tanaka; Dongshu Chen; Donald Kufe; Jianlin Gong
Journal:  J Immunol       Date:  2002-03-01       Impact factor: 5.422

Review 4.  Chemoprevention in hereditary colorectal cancer syndromes.

Authors:  E Hawk; R Lubet; P Limburg
Journal:  Cancer       Date:  1999-12-01       Impact factor: 6.860

5.  Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells.

Authors:  D Boczkowski; S K Nair; J H Nam; H K Lyerly; E Gilboa
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

6.  Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice.

Authors:  S Homma; G Toda; J Gong; D Kufe; T Ohno
Journal:  J Gastroenterol       Date:  2001-11       Impact factor: 7.527

7.  Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells.

Authors:  J Gong; D Avigan; D Chen; Z Wu; S Koido; M Kashiwaba; D Kufe
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

8.  Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model.

Authors:  Y Akasaki; T Kikuchi; S Homma; T Abe; D Kofe; T Ohno
Journal:  J Immunother       Date:  2001 Mar-Apr       Impact factor: 4.456

9.  Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12.

Authors:  Jianlin Gong; Shigeo Koido; Dongshu Chen; Yasuhiro Tanaka; Lei Huang; David Avigan; Kenneth Anderson; Tsuneya Ohno; Donald Kufe
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

10.  Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.

Authors:  L H Butterfield; S M Jilani; N G Chakraborty; L A Bui; A Ribas; V B Dissette; R Lau; S C Gamradt; J A Glaspy; W H McBride; B Mukherji; J S Economou
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

View more
  12 in total

Review 1.  Enhancement of dendritic cells as vaccines for cancer.

Authors:  Meghan E Turnis; Cliona M Rooney
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

Review 2.  Cancer vaccine by fusions of dendritic and cancer cells.

Authors:  Shigeo Koido; Eiichi Hara; Sadamu Homma; Yoshihisa Namiki; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Clin Dev Immunol       Date:  2010-02-18

3.  Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.

Authors:  Sadamu Homma; Hideo Komita; Yukiko Sagawa; Tsuneya Ohno; Gotaro Toda
Journal:  Immunology       Date:  2005-08       Impact factor: 7.397

4.  Antigen-specific polyclonal cytotoxic T lymphocytes induced by fusions of dendritic cells and tumor cells.

Authors:  Shigeo Koido; Sadamu Homma; Eiichi Hara; Yoshihisa Namiki; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  J Biomed Biotechnol       Date:  2010-04-07

5.  Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.

Authors:  Adam E Snook; Peng Li; Benjamin J Stafford; Elizabeth J Faul; Lan Huang; Ruth C Birbe; Alessandro Bombonati; Stephanie Schulz; Matthias J Schnell; Laurence C Eisenlohr; Scott A Waldman
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 6.  Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy.

Authors:  Michael J Browning
Journal:  Hum Vaccin Immunother       Date:  2013-03-08       Impact factor: 3.452

7.  Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses.

Authors:  S Homma; Y Sagawa; M Ito; T Ohno; G Toda
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

8.  Antigenic stimulation with cytochrome P450 2J expressed in mouse hepatocellular carcinoma cells regulates host anti-tumour immunity.

Authors:  S Homma; S Koido; Y Sagawa; H Suzuki; H Komita; E Nagasaki; A Takahara; J Horiguchi-Yamada; H Tajiri; D C Zeldin; T Obata
Journal:  Clin Exp Immunol       Date:  2009-03-02       Impact factor: 4.330

Review 9.  Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines.

Authors:  Shigeo Koido; Sadamu Homma; Akitaka Takahara; Yoshihisa Namiki; Hideo Komita; Eijiro Nagasaki; Masaki Ito; Keisuke Nagatsuma; Kan Uchiyama; Kenichi Satoh; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  J Biomed Biotechnol       Date:  2011-04-26

Review 10.  Regulation of tumor immunity by tumor/dendritic cell fusions.

Authors:  Shigeo Koido; Sadamu Homma; Eiichi Hara; Yoshihisa Namiki; Akitaka Takahara; Hideo Komita; Eijiro Nagasaki; Masaki Ito; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Clin Dev Immunol       Date:  2010-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.